Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2017-09-01
2018-03-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC)
NCT01574430
The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
NCT01630863
The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC
NCT03692169
Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy
NCT05687422
Different Doses of vPDT in the Treatment of cCSC
NCT05390619
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OCTA group
Patients in this group underwent OCTA-guided half-dose photodynamic therapy.
OCTA-guided Photodynamic therapy
Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
ICGA group
Patients in this group underwent normal ICGA-guided half dose photodynamic therapy.
ICGA-guided Photodynamic therapy
Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OCTA-guided Photodynamic therapy
Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
ICGA-guided Photodynamic therapy
Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of SRF and/or serous pigment epithelial detachment on OCT
* Presence of abnormal dilated choroidal vasculature in ICGA
Exclusion Criteria
* Any disease that may affect the quality of imaging (quality of OCTA images \< 6), such as cataract, high myopia or nystagmus
* History of ocular surgeries including retinal laser
* Pregnancy
* Any uncontrolled systemic disease
* Any condition rendering patients intolerable to image acquisition
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Natural Science Foundation of China
OTHER_GOV
Peking University People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mingwei Zhao
Head of Ophthalmology, Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mingwei Zhao, M.D
Role: STUDY_DIRECTOR
Peking University People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
People's Hospital of Peking University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hu J, Qu J, Li M, Sun G, Piao Z, Liang Z, Yao Y, Sadda S, Zhao M. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2021 Jan 1;41(1):189-198. doi: 10.1097/IAE.0000000000002795.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Peking UPH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.